A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of DA-9701 (Motilitone) in Patients With Constipation-type Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Pilot Study

Overview

Journal J Neurogastroenterol Motil

Date 2022 Mar 2

PMID 35232894

Authors

Ju Yup Lee

Nayoung Kim

Hyuk Yoon

Cheol Min Shin

Young Soo Park

Dong Ho Lee

Affiliations

Soon will be listed here.

Abstract

Background/aims: To assess the effects and safety of DA-9701 (Motilitone) in patients with constipation-type irritable bowel syndrome (IBS-C) which frequently accompany functional dyspepsia (FD).

Methods: FD and IBS-C were diagnosed based on the Rome III criteria. Randomized subjects were administered 30 mg of DA-9701 or placebo 3 times a day for 4 weeks. The study endpoints were evaluated the percentage of responders in the overall symptom evaluation of IBS-C and FD.

Results: Thirty IBS-C patients and 30 placebos were prospectively enrolled. The proportion of responders with improvement in overall symptoms of IBS-C was 53.33% in the DA-9701 group and 40.00% in the placebo group ( = 0.301). Compared to the placebo group, the decrease of abdominal pain score in the DA-9701 group was significantly higher at week 3 in the DA-9701 group (0.96 ± 0.77 vs 0.55 ± 0.79, = 0.042) but no significance at week 4. There was no significant difference in total IBS quality of life score at week 4 between the 2 groups ( = 0.897). Among patients with IBS-C accompanied by FD, the proportion of responders in the DA- 9701 group was 50.00% (15/30), which was higher than 31.03% (9/29) of the placebo group ( = 0.138).

Conclusions: DA-9701 showed trend of treatment efficacy in patients with IBS-C and FD overlap including overall improvement, and safety, compared to placebo but without significance probably due to small numbers. It is suggested the need for a large-scale clinical trial to confirm this preliminary effect of DA-9701.

Citing Articles

Intestinal tryptophan metabolism in disease prevention and swine production.

Hu Z, Feng L, Jiang Q, Wang W, Tan B, Tang X Anim Nutr. 2023; 15:364-374.

PMID: 38058568 PMC: 10695851. DOI: 10.1016/j.aninu.2023.08.002.

References

Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

Lembo A, Cremonini F, Meyers N, Hickling R . Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther. 2010; 31(9):979-90. DOI: 10.1111/j.1365-2036.2010.04265.x. View

Patrick D, Drossman D, Frederick I, DiCesare J, Puder K . Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998; 43(2):400-11. DOI: 10.1023/a:1018831127942. View

Min Y, Min B, Kim S, Choi D, Rhee P . Effect of DA-9701 on Gastric Motor Function Assessed by Magnetic Resonance Imaging in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial. PLoS One. 2015; 10(9):e0138927. PMC: 4581730. DOI: 10.1371/journal.pone.0138927. View

Drossman D, Morris C, Hu Y, Toner B, Diamant N, Whitehead W . Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007; 102(7):1442-53. DOI: 10.1111/j.1572-0241.2007.01283.x. View

Asagarasu A, Matsui T, Hayashi H, Tamaoki S, Yamauchi Y, Sato M . Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS). Chem Pharm Bull (Tokyo). 2009; 57(1):34-42. DOI: 10.1248/cpb.57.34. View

Gershon M, Tack J . The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132(1):397-414. DOI: 10.1053/j.gastro.2006.11.002. View

Park H . Functional gastrointestinal disorders and overlap syndrome in Korea. J Gastroenterol Hepatol. 2011; 26 Suppl 3:12-4. DOI: 10.1111/j.1440-1746.2011.06644.x. View

von Wulffen M, Talley N, Hammer J, McMaster J, Rich G, Shah A . Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2018; 64(2):480-486. DOI: 10.1007/s10620-018-5343-6. View

10.

Lee S, Ryu H, Choi S, Jang S . Psychological Factors Influence the Overlap Syndrome in Functional Gastrointestinal Disorder and Quality of Life among Psychiatric Patients in South Korea. Psychiatry Investig. 2020; 17(3):262-267. PMC: 7113182. DOI: 10.30773/pi.2019.0278. View

11.

De Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E . Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018; 31(6):639-648. PMC: 6191868. DOI: 10.20524/aog.2018.0314. View

12.

Cinca R, Chera D, Gruss H, Halphen M . Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. Aliment Pharmacol Ther. 2013; 37(9):876-86. DOI: 10.1111/apt.12278. View

13.

Browne R . On the use of a pilot sample for sample size determination. Stat Med. 1995; 14(17):1933-40. DOI: 10.1002/sim.4780141709. View

14.

Kim Y, Choi S, Park J, Choi C, Lee D, Son H . The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipation. J Neurogastroenterol Motil. 2010; 16(1):61-70. PMC: 2879829. DOI: 10.5056/jnm.2010.16.1.61. View

15.

Kwon Y, Son M . DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia. Biomol Ther (Seoul). 2013; 21(3):181-9. PMC: 3830115. DOI: 10.4062/biomolther.2012.096. View

16.

Kim Y, Kim N . Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018; 24(4):544-558. PMC: 6175559. DOI: 10.5056/jnm18082. View

17.

Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

18.

Chey W, Pare P, Viegas A, Ligozio G, Shetzline M . Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol. 2008; 103(5):1217-25. DOI: 10.1111/j.1572-0241.2008.01808.x. View

19.

Choi S, Choi J, Jun J, Koh J, Kim S, Kim D . Induction of pacemaker currents by DA-9701, a prokinetic agent, in interstitial cells of Cajal from murine small intestine. Mol Cells. 2009; 27(3):307-12. DOI: 10.1007/s10059-009-0039-6. View

20.

Park J, Choi M, Kim Y, Choi C, Choi S, Hong S . Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res. 2009; 18(4):435-46. DOI: 10.1007/s11136-009-9461-7. View